|
|
Article: Strong competition ahead for drug-eluting stents, despite their growing availability.(Strategic Notes)
- Article from:
- Healthcare Strategic Management
- Article date:
- December 1, 2003
CopyrightCOPYRIGHT 2003 HCPro, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
In a recent study entitled "Drug-Eluting Stents: Physician Perspectives and Opportunity Analysis of a High Growth Market," analysts from Front Line Strategic Consulting, San Mateo, Calif., found there will be strong competition among hospitals for drug-eluting stents even as more companies are poised to enter the U.S. market by 2008.
According to Front Line, the worldwide market for these stents, which add medication to the mechanical function of keeping clogged arteries open, is currently $2.1 billion. That will rise to $6.3 billion in 2008, driven by an increasing patient population and broader applications for the stents.
The U.S. will represent 70% ...